Tools
Waardenburg Syndrome
Introduction
Waardenburg syndrome encompasses a group of genetic disorders, most commonly inherited in an autosomal dominant pattern. The syndrome is named after Dutch ophthalmologist and geneticist Petrus Johannes Waardenburg, who first described it in 1951.[1] Pathogenic mutations disrupt the migration and proliferation of neural crest cells during embryogenesis. Because melanocytes develop from the neural crest, individuals affected by this condition exhibit abnormal melanocyte distribution, resulting in patchy depigmentation.
This rare disorder involves loss of pigment-producing cells in the eyes, skin, hair, and the stria vascularis of the cochlea.[2] Clinical presentation varies, but hallmark features include a broad nasal root, hypertelorism with dystopia of the lacrimal puncta, heterochromia or hypopigmented irides, medial eyebrow hypertrichosis, a white forelock, and congenital sensorineural hearing loss (SNHL).[3]
Although no curative treatment is available, supportive care may include cochlear implantation and surgical management of associated conditions, such as Hirschsprung disease. Genetic counseling has a key role in facilitating early diagnosis, risk assessment, and informed family planning.[4]
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
Waardenburg syndrome is most often inherited in an autosomal dominant pattern. Various gene mutations—including insertions, deletions, frameshifts, missense, and nonsense variants—interfere with neural crest cell migration and differentiation during embryogenesis, leading to the characteristic clinical features of the syndrome.[5] Penetrance and expressivity vary depending on the specific gene involved.
A total of 4 clinical subtypes of Waardenburg syndrome have been identified, as mentioned below.
- Type 1, one of the most common forms, results from mutations in the PAX3 gene and is typically characterized by congenital SNHL, dystopia canthorum (lateral displacement of the inner canthi), neural tube defects, cleft lip or palate, and patchy depigmentation of the skin and hair.[6] Ocular pigmentary abnormalities also frequently accompany these features.
- Type 2, another common form, arises from mutations in the MITF gene.[7] Unlike type 1, individuals with type 2 do not exhibit dystopia canthorum but share other clinical features.
- Type 3 is considered a more severe variant of type 1 and includes additional musculoskeletal abnormalities, particularly affecting the upper limbs.[8]
- Type 4 is typically inherited in an autosomal recessive manner and is caused by mutations in EDNRB or EDN3, which encode endothelin receptor type B and endothelin-3, respectively. This subtype may be associated with Hirschsprung disease due to involvement of the enteric nervous system.[9]
Epidemiology
The prevalence of Waardenburg syndrome varies geographically. In the Netherlands, the estimated incidence is approximately 1 in 212,000 individuals, with low penetrance observed in about 20% of cases. Globally, the estimated prevalence is approximately 1 in 42,000 individuals. Types 1 and 2 of Waardenburg syndrome are the most frequently reported subtypes worldwide, whereas type 3 remains exceedingly rare.[10] Type 4 accounts for approximately 19% of all reported cases.[11]
Among individuals with deaf-mutism, Waardenburg syndrome occurs in 0.9% to 2.8%. The condition affects all racial and ethnic groups equally and demonstrates no sex predilection. Although diagnosis is often made at birth based on characteristic physical features, some pigmentary changes may become more apparent with age.
Pathophysiology
Waardenburg syndrome is a genetic disorder most commonly inherited in an autosomal dominant pattern. Several hypotheses have been proposed to explain its pathogenesis and the variability among clinical subtypes. The most widely accepted explanation is the neural crest theory, which attributes the disorder to abnormalities in the differentiation and migration of neural crest cells during embryogenesis. This theory also accounts for the association between Waardenburg syndrome and Hirschsprung disease, as both conditions involve disrupted development of neural crest cells. First arch syndrome, resulting from the failure of neural crest cells to migrate into the first pharyngeal arch, shares overlapping clinical features with Waardenburg syndrome.[12][13]
Type 1 Waardenburg syndrome
In type 1 Waardenburg syndrome, mutations occur in the PAX3 gene, located on chromosome 2q36.1. The PAX3 gene encodes a transcription factor that primarily functions as a transcriptional activator but may also act as a repressor for specific target genes.[14] During embryonic development, PAX3 is expressed in progenitor cells that contribute to the formation of skeletal muscle, the nervous system, and the lateral margins of the neural plate—regions that give rise to neural crest cells.[15][16] As development progresses, PAX3 expression emerges in melanoblasts, Schwann cell precursors, and structures of the inner ear and mandible. Additionally, translation of this gene is crucial in defining the location of the nasion.[16][17]
Type 2 Waardenburg syndrome
In type 2 Waardenburg syndrome, mutations affect the MITF gene located on chromosome 3p13. This gene encodes a transcription factor expressed in melanocytes, osteoclasts, and mast cells.[18] The MITF protein is essential for melanin production, DNA repair, mitotic regulation, membrane trafficking, and mitochondrial function. These diverse roles account for the pigmentation abnormalities and SNHL observed in type 2 Waardenburg syndrome, as well as its involvement in other conditions, such as Tietze syndrome and melanoma.[19][20][21]
Type 3 Waardenburg syndrome
Type 3 Waardenburg syndrome, the rarest variant, results from mutations in the PAX3 gene, similar to those in type 1.[22] Diagnosis is clinical and based on characteristic features of hypopigmentation and SNHL in combination with limb anomalies.[23] Upper limb involvement is more common and may include hypoplasia and flexion contractures. Homozygous PAX3 mutations are typically associated with more severe musculoskeletal manifestations than heterozygous mutations.[24] Type 3 is also referred to as Klein-Waardenburg syndrome.[25]
Type 4 Waardenburg syndrome
Type 4 Waardenburg syndrome combines the classic pigmentary abnormalities and SNHL, which are characteristic of Waardenburg syndrome, with aganglionic megacolon, and is consistent with Hirschsprung disease.[26] This subtype, also known as Waardenburg-Hirschsprung syndrome or Waardenburg-Shah syndrome, includes 3 genetically distinct forms.[27]
- Type 4A results from mutations in the EDNRB gene located on chromosome 13q22.3, which encodes the endothelin B receptor.[28]
- Type 4B involves mutations in the EDN3 gene located on chromosome 20q13.32, which encodes an endothelin receptor ligand.
- Type 4C arises from mutations in the SOX10 gene located on chromosome 22q13.1, which encodes a transcription factor critical for neural crest development.[29]
Individuals with heterozygous mutations in types 4A and 4B may be asymptomatic or exhibit only mild clinical features. In contrast, truncating mutations in SOX10, associated with type 4C, often result in more severe clinical phenotypes and are frequently accompanied by additional neurological abnormalities.[30]
Several etiological theories have been proposed to explain Waardenburg syndrome, including intrauterine necrosis and associations with status dysraphicus; however, none fully account for its diverse clinical features. Inherited forms of deafness contribute to approximately 50% of congenital hearing loss, with about 70% of these cases involving mutations in single genes that directly impair auditory function. Syndromic forms of deafness, including that seen in Waardenburg syndrome, are often associated with additional developmental anomalies. In Waardenburg syndrome, hearing loss is typically caused by mutations in the MITF gene in type 2 and the PAX3 gene in type 1. Type 4 involves mutations in genes encoding the endothelin B receptor (EDNRB) or its ligand, endothelin 3 (EDN3).
Histopathology
The characteristic histopathological feature of Waardenburg syndrome is the absence or severe reduction of melanocytes, although residual dihydroxyphenylalanine-positive cells may be present. In hypopigmented skin, melanosomes or indeterminate dendritic cells can be observed within keratinocytes. Langerhans cells in the epidermis appear normal. The density of pigment cells is reduced at the margins of depigmented areas, which is often accompanied by nuclear and cytoplasmic abnormalities. Vacuolated cells may display a clear halo surrounded by melanosomes.[31] Histopathological examination of the inner ear at autopsy reveals spiral ganglion atrophy and a reduction in nerve fibers, accompanied by the absence of the organ of Corti.[32]
History and Physical
Clinically, Waardenburg syndrome is often identified by characteristic morphological features that manifest after birth. A detailed physical examination and comprehensive family history form the foundation of the diagnostic evaluation. Typical features include a white forelock, broad nasal root, and heterochromia irides (differences in eye color). Some children may fail initial newborn hearing screening, if conducted, whereas others may raise concerns later due to a lack of auditory responsiveness. Not all individuals with Waardenburg syndrome exhibit every clinical feature. Based on genetic mutations and clinical presentation, 4 distinct types of Waardenburg syndrome have been described.
- Type 1 is characterized by dystopia canthorum, a broad nasal root, a short philtrum, and a short retropositional maxilla.
- Type 2 presents with normally positioned canthi, SNHL, and heterochromia irides.
- Type 3, also known as Klein-Waardenburg syndrome, shares features with type 1, but includes prominent musculoskeletal abnormalities, such as underdeveloped carpal bones, aplasia of the first and second ribs, sacral cysts, limb anomalies, and muscle hypoplasia with syndactyly. In some cases, type 3 includes the full spectrum of primary features along with severe skeletal deformities, microcephaly, and intellectual disability.
- Type 4, also known as Waardenburg-Shah syndrome, resembles type 2 clinically but is distinguished by the presence of congenital aganglionic megacolon consistent with Hirschsprung disease.
Pigmentary changes in Waardenburg syndrome involve the skin, hair, and eyes. Skin manifestations may include achromic patches and hyperpigmented macules superimposed on normally pigmented areas. Ocular abnormalities commonly feature heterochromia iridis or bilateral isohypochromia. Diagnosis is primarily clinical and guided by established major and minor criteria (see Table below).[33] A clinical diagnosis of type 1 Waardenburg syndrome requires the presence of either 2 major criteria or 1 major and 2 minor criteria.[34]
Table. Major and Minor Diagnostic Criteria for Waardenburg Syndrome
|
Major Criteria |
Minor Criteria |
|
Heterochromia iridis |
Broad nasal root |
|
Sensorineural hearing loss |
White macules or patches on the skin |
|
White forelock |
Synophrys |
|
Lateral displacement of inner canthi |
Premature graying of hair |
|
Affected first-degree relative |
Hypoplasia of the nasal alae |
Evaluation
Types 1 and 3 Waardenburg syndrome are the most common variants. The point mutations responsible can be detected using multiplex ligation-dependent probe amplification targeting specific genes. Formal measurements of interpupillary and intercanthal distances should be taken and compared with normative charts when there is uncertainty in distinguishing hypertelorism from telecanthus. A comprehensive audiogram is essential, and depending on the patient’s age, auditory brainstem response testing may provide the most accurate assessment of hearing.[35]
No specific radiological tests are recommended for evaluating Waardenburg syndrome. However, imaging of the middle ear structures and cochlea may be necessary, depending on the clinical presentation and genetic findings. High-resolution computed tomography (CT) or, in some cases, magnetic resonance imaging (MRI) can be used when imaging is warranted.[36]
Treatment / Management
Waardenburg syndrome is a genetic disorder without a definitive treatment.[37] Early identification and intervention for hearing impairments in affected children are crucial to support optimal language development, comprehension, and social integration. Hearing aids may be beneficial depending on the severity of hearing loss, while cochlear implantation is often required for congenital deafness. Sun protection is recommended for hypopigmented skin patches due to their increased susceptibility to UV damage.[38] Genetic counseling is a critical component in the care of individuals with this condition.
Differential Diagnosis
Several conditions may present with overlapping features and should be considered in the differential diagnosis of Waardenburg syndrome. These disorders often involve pigmentary changes, auditory abnormalities, or other systemic manifestations that require careful clinical distinction.
- Piebaldism: A genetic disorder characterized by congenital depigmentation of the skin and hair, typically presenting with a stable, nonprogressive course. Please see StatPearls' companion resource, "Piebaldism," for more information.
- Tietze syndrome: A rare genetic disorder characterized by profound congenital deafness and generalized hypopigmentation. Musculoskeletal abnormalities may also be present.
- Oculocutaneous albinism: A group of genetic disorders resulting from impaired melanin synthesis, leading to diffuse depigmentation of the skin, hair, and eyes.
- Vogt-Koyanagi-Harada disease: An autoimmune condition affecting the skin, eyes, inner ear, and central nervous system, often presenting with uveitis, vitiligo, and hearing loss.
- Vitiligo: An acquired condition that presents with progressive depigmented macules on the skin and, occasionally, hair.
Accurate diagnosis relies on a detailed clinical history, physical examination, and genetic testing when appropriate. Differentiating Waardenburg syndrome from these conditions is essential for guiding management, prognosis, and genetic counseling.
Prognosis
Waardenburg syndrome is a chronic condition; however, individuals affected by this condition typically have a normal life expectancy. Morbidity stems from abnormalities in neural crest–derived tissues and may include intellectual disability, deafness, ocular disorders such as cataracts, skeletal anomalies, and psychiatric conditions.[39] These clinical features reflect the underlying genetic mutations causing the disease. Homozygous mutations often lead to more severe manifestations than heterozygous mutations, with certain variants, particularly type 4, generally associated with greater severity
Complications
The complications of Waardenburg syndrome vary depending on the subtype. Type 1 may be associated with blepharophimosis, whereas type 2 is commonly characterized by SNHL, which occurs in approximately 70% of cases. Type 3 is distinguished by skeletal anomalies and, in more severe cases, intellectual disability and microcephaly. The primary complication of type 4 is congenital aganglionic megacolon, also known as Hirschsprung disease.[40]
Consultations
Consultation with a geneticist is essential in the management of Waardenburg syndrome, particularly because type 1 follows an autosomal dominant inheritance pattern and often occurs within families. Although prenatal testing can detect pathogenic mutations, it does not reliably predict the severity of clinical manifestations. Effective management requires an interprofessional healthcare team, including audiologists, dermatologists, ophthalmologists, and surgeons, to ensure early intervention and comprehensive care for the syndrome’s multisystem complications.
Deterrence and Patient Education
Life expectancy is generally normal in children with Waardenburg syndrome. Genetic counseling is crucial, as a single affected gene can be passed to future generations. Without a definitive treatment, educating patients and families about symptom-based management is essential. Morbidity arises from defects in neural crest–derived tissues.[41]
Enhancing Healthcare Team Outcomes
Waardenburg syndrome presents complex challenges and is best managed by an interprofessional team of healthcare providers capable of addressing its broad spectrum of complications. Psychosocial functioning and quality of life may be significantly impacted, especially when psychiatric conditions coexist. Effective management often involves collaboration among dermatologists, psychiatrists, ophthalmologists, neurologists, and rheumatologists. Dermatology-trained nurses play a crucial role in patient education, support, treatment guidance, and monitoring for complications. Effective communication within the healthcare team is crucial for optimizing patient outcomes.[42]
References
Sil A, Panigrahi A. Visual Dermatology: Waardenburg Syndrome Type II. Journal of cutaneous medicine and surgery. 2020 May/Jun:24(3):305. doi: 10.1177/1203475420902048. Epub [PubMed PMID: 32421428]
Tan J, Duron A, Sucov HM, Makita T. Placode and neural crest origins of congenital deafness in mouse models of Waardenburg-Shah syndrome. iScience. 2025 Jan 17:28(1):111680. doi: 10.1016/j.isci.2024.111680. Epub 2024 Dec 24 [PubMed PMID: 39868048]
Grewal PS, Knight H, Michaelides M. Asymmetric choroidal hypopigmentation in a Son and mother with Waardenburg syndrome type I. Ophthalmic genetics. 2020 Jun:41(3):284-287. doi: 10.1080/13816810.2020.1750037. Epub 2020 Apr 13 [PubMed PMID: 32281454]
Yu Y, Liu W, Chen M, Yang Y, Yang Y, Hong E, Lu J, Zheng J, Ni X, Guo Y, Zhang J. Two novel mutations of PAX3 and SOX10 were characterized as genetic causes of Waardenburg Syndrome. Molecular genetics & genomic medicine. 2020 May:8(5):e1217. doi: 10.1002/mgg3.1217. Epub 2020 Mar 13 [PubMed PMID: 32168437]
Alehabib E, Alinaghi S, Pourfatemi F, Darvish H. Incomplete penetrance of MITF gene c.943C}T mutation in an extended family with Waardenburg syndrome type II. International journal of pediatric otorhinolaryngology. 2020 Aug:135():110014. doi: 10.1016/j.ijporl.2020.110014. Epub 2020 Apr 21 [PubMed PMID: 32422366]
Agrawal R, Walia S. Waardenburg Syndrome Type 1. Indian journal of ophthalmology. 2022 Jul:70(7):2679-2681. doi: 10.4103/ijo.IJO_3003_21. Epub [PubMed PMID: 35791202]
Ren SM, Kong XD, Wu QH, Jiao ZH, Chen C, Qin ZB. [Analysis of genetic variation in patients with Waardenburg syndrome type Ⅱ by next generation sequencing]. Zhonghua yi xue za zhi. 2020 Mar 24:100(11):853-858. doi: 10.3760/cma.j.cn112137-20190730-01692. Epub [PubMed PMID: 32234158]
Level 2 (mid-level) evidenceTekin M, Bodurtha JN, Nance WE, Pandya A. Waardenburg syndrome type 3 (Klein-Waardenburg syndrome) segregating with a heterozygous deletion in the paired box domain of PAX3: a simple variant or a true syndrome? Clinical genetics. 2001 Oct:60(4):301-4 [PubMed PMID: 11683776]
Chandra Mohan SLN. Case of Waardenburg Shah syndrome in a family with review of literature. Journal of otology. 2018 Sep:13(3):105-110. doi: 10.1016/j.joto.2018.05.005. Epub 2018 Jun 8 [PubMed PMID: 30559775]
Level 3 (low-level) evidenceApaydin F, Bereketoglu M, Turan O, Hribar K, Maassen MM, Günhan O, Zenner HP, Pfister M. [Waardenburg syndrome. A heterogenic disorder with variable penetrance]. HNO. 2004 Jun:52(6):533-7 [PubMed PMID: 15029423]
Song J, Feng Y, Acke FR, Coucke P, Vleminckx K, Dhooge IJ. Hearing loss in Waardenburg syndrome: a systematic review. Clinical genetics. 2016 Apr:89(4):416-425. doi: 10.1111/cge.12631. Epub 2015 Jul 17 [PubMed PMID: 26100139]
Level 1 (high-level) evidenceLi S, Guo M, Ruan B, Liu Y, Cui X, Han W, Li R. A Novel PAX3 Mutation in a Chinese Family with Waardenburg Syndrome Type 1. Genetic testing and molecular biomarkers. 2020 May:24(5):249-255. doi: 10.1089/gtmb.2019.0231. Epub 2020 Apr 3 [PubMed PMID: 32250160]
Johnson JM, Moonis G, Green GE, Carmody R, Burbank HN. Syndromes of the first and second branchial arches, part 1: embryology and characteristic defects. AJNR. American journal of neuroradiology. 2011 Jan:32(1):14-9. doi: 10.3174/ajnr.A2072. Epub 2010 Mar 18 [PubMed PMID: 20299437]
Mayanil CS, George D, Freilich L, Miljan EJ, Mania-Farnell B, McLone DG, Bremer EG. Microarray analysis detects novel Pax3 downstream target genes. The Journal of biological chemistry. 2001 Dec 28:276(52):49299-309 [PubMed PMID: 11590174]
Buckingham M, Relaix F. The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions. Annual review of cell and developmental biology. 2007:23():645-73 [PubMed PMID: 17506689]
Monsoro-Burq AH. PAX transcription factors in neural crest development. Seminars in cell & developmental biology. 2015 Aug:44():87-96. doi: 10.1016/j.semcdb.2015.09.015. Epub 2015 Sep 26 [PubMed PMID: 26410165]
Wu M, Li J, Engleka KA, Zhou B, Lu MM, Plotkin JB, Epstein JA. Persistent expression of Pax3 in the neural crest causes cleft palate and defective osteogenesis in mice. The Journal of clinical investigation. 2008 Jun:118(6):2076-87. doi: 10.1172/JCI33715. Epub [PubMed PMID: 18483623]
Hershey CL, Fisher DE. Mitf and Tfe3: members of a b-HLH-ZIP transcription factor family essential for osteoclast development and function. Bone. 2004 Apr:34(4):689-96 [PubMed PMID: 15050900]
Garraway LA, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. Nature reviews. Cancer. 2006 Aug:6(8):593-602 [PubMed PMID: 16862190]
Cheli Y, Ohanna M, Ballotti R, Bertolotto C. Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment cell & melanoma research. 2010 Feb:23(1):27-40. doi: 10.1111/j.1755-148X.2009.00653.x. Epub 2009 Nov 25 [PubMed PMID: 19995375]
Smith SD, Kelley PM, Kenyon JB, Hoover D. Tietz syndrome (hypopigmentation/deafness) caused by mutation of MITF. Journal of medical genetics. 2000 Jun:37(6):446-8 [PubMed PMID: 10851256]
Li S, Qin M, Mao S, Mei L, Cai X, Feng Y, He C, Song J. A comprehensive genotype-phenotype evaluation of eight Chinese probands with Waardenburg syndrome. BMC medical genomics. 2022 Nov 3:15(1):230. doi: 10.1186/s12920-022-01379-6. Epub 2022 Nov 3 [PubMed PMID: 36329483]
Level 2 (mid-level) evidenceSomashekar PH, Upadhyai P, Narayanan DL, Kamath N, Bajaj S, Girisha KM, Shukla A. Phenotypic diversity and genetic complexity of PAX3-related Waardenburg syndrome. American journal of medical genetics. Part A. 2020 Dec:182(12):2951-2958. doi: 10.1002/ajmg.a.61893. Epub 2020 Sep 29 [PubMed PMID: 32990402]
Salah S, Meiner V, Abumayaleh A, Asafra A, Al-Sharif T, Al-Fallah O, Hasasneh B, Zlotogora J. Biallelic variants in PAX3 cause Klein syndrome. Clinical genetics. 2022 Sep:102(3):223-227. doi: 10.1111/cge.14167. Epub 2022 Jun 5 [PubMed PMID: 35607853]
Saberi M, Golchehre Z, Salmani H, Karamzade A, Tabatabaie SZ, Keramatipour M. First report of Klein-Waardenburg Syndrome in Iran and a novel pathogenic splice site variant in PAX3 gene. International journal of pediatric otorhinolaryngology. 2018 Oct:113():229-233. doi: 10.1016/j.ijporl.2018.08.009. Epub 2018 Aug 10 [PubMed PMID: 30173992]
Jabeen R, Babar ME, Ahmad J, Awan AR. Novel mutations of endothelin-B receptor gene in Pakistani patients with Waardenburg syndrome. Molecular biology reports. 2012 Jan:39(1):785-8. doi: 10.1007/s11033-011-0799-x. Epub 2011 May 6 [PubMed PMID: 21547364]
Read AP, Newton VE. Waardenburg syndrome. Journal of medical genetics. 1997 Aug:34(8):656-65 [PubMed PMID: 9279758]
Pingault V, Ente D, Dastot-Le Moal F, Goossens M, Marlin S, Bondurand N. Review and update of mutations causing Waardenburg syndrome. Human mutation. 2010 Apr:31(4):391-406. doi: 10.1002/humu.21211. Epub [PubMed PMID: 20127975]
Fernández RM, Núñez-Ramos R, Enguix-Riego MV, Román-Rodríguez FJ, Galán-Gómez E, Blesa-Sánchez E, Antiñolo G, Núñez-Núñez R, Borrego S. Waardenburg syndrome type 4: report of two new cases caused by SOX10 mutations in Spain. American journal of medical genetics. Part A. 2014 Feb:164A(2):542-7. doi: 10.1002/ajmg.a.36302. Epub 2013 Dec 5 [PubMed PMID: 24311220]
Level 3 (low-level) evidencePingault V, Zerad L, Bertani-Torres W, Bondurand N. SOX10: 20 years of phenotypic plurality and current understanding of its developmental function. Journal of medical genetics. 2022 Feb:59(2):105-114. doi: 10.1136/jmedgenet-2021-108105. Epub 2021 Oct 19 [PubMed PMID: 34667088]
Level 3 (low-level) evidenceEz-Zahraoui M, Lezrek O, Cherkaoui O. [Waardenburg syndrome type 1]. Journal francais d'ophtalmologie. 2019 Jan:42(1):94-95. doi: 10.1016/j.jfo.2018.03.028. Epub 2018 Dec 13 [PubMed PMID: 30554874]
Brizzolara A, Torre M, Favre A, Pini Prato A, Bocciardi R, Martucciello G. Histochemical study of Dom mouse: A model for Waardenburg-Hirschsprung's phenotype. Journal of pediatric surgery. 2004 Jul:39(7):1098-103 [PubMed PMID: 15213907]
Astakhov YS, Tultseva SN, Lisochkina AB, Takhtaev YV, Astakhov SY, Shakhnazarova AA. [Ophthalmologic manifestations of Waardenburg syndrome]. Vestnik oftalmologii. 2019:135(6):91-99. doi: 10.17116/oftalma201913506191. Epub [PubMed PMID: 32015313]
Gowda VK, Srinivas S, Srinivasan VM. Waardenburg Syndrome Type I. Indian journal of pediatrics. 2020 Mar:87(3):244. doi: 10.1007/s12098-019-03170-5. Epub 2020 Jan 27 [PubMed PMID: 31989460]
Fan W, Ni K, Chen F, Li X. Hearing characteristics and cochlear implant effects in children with Waardenburg syndrome: a case series. Translational pediatrics. 2022 Jul:11(7):1234-1241. doi: 10.21037/tp-22-271. Epub [PubMed PMID: 35958009]
Level 2 (mid-level) evidenceKontorinis G, Goetz F, Lanfermann H, Luytenski S, Giesemann AM. Inner ear anatomy in Waardenburg syndrome: radiological assessment and comparison with normative data. International journal of pediatric otorhinolaryngology. 2014 Aug:78(8):1320-6. doi: 10.1016/j.ijporl.2014.05.020. Epub 2014 May 24 [PubMed PMID: 24882458]
Ren S, Chen X, Kong X, Chen Y, Wu Q, Jiao Z, Shi H. Identification of six novel variants in Waardenburg syndrome type II by next-generation sequencing. Molecular genetics & genomic medicine. 2020 Mar:8(3):e1128. doi: 10.1002/mgg3.1128. Epub 2020 Jan 20 [PubMed PMID: 31960627]
Wallis KE, Blum NJ, Waryasz SA, Augustyn M. Bilateral Cochlear Implants: Maximizing Expected Outcomes. Journal of developmental and behavioral pediatrics : JDBP. 2018 Feb/Mar:39(2):177-179. doi: 10.1097/DBP.0000000000000547. Epub [PubMed PMID: 29324475]
Minami SB, Nara K, Mutai H, Morimoto N, Sakamoto H, Takiguchi T, Kaga K, Matsunaga T. A clinical and genetic study of 16 Japanese families with Waardenburg syndrome. Gene. 2019 Jul 1:704():86-90. doi: 10.1016/j.gene.2019.04.023. Epub 2019 Apr 10 [PubMed PMID: 30978479]
Raissi D, Christie A, Applegate K. Waardenburg Syndrome and Left Persistent Superior Vena Cava. Journal of clinical imaging science. 2018:8():44. doi: 10.4103/jcis.JCIS_31_18. Epub 2018 Nov 15 [PubMed PMID: 30546928]
Boutkhil M, Benchekroun Belabess S, El Ikhloufi M, Taouri N, Cherkaoui O. [Waardenburg syndrome, a family story]. Journal francais d'ophtalmologie. 2019 Sep:42(7):e319-e324. doi: 10.1016/j.jfo.2018.12.026. Epub 2019 May 24 [PubMed PMID: 31130388]
Shrinkhal, Singh A, Mittal SK, Agrawal A, Verma R, Yadav P. Waardenburg syndrome with dry eyes: A rare association. Taiwan journal of ophthalmology. 2019 Jul-Sep:9(3):198-201. doi: 10.4103/tjo.tjo_103_18. Epub 2019 Sep 12 [PubMed PMID: 31572658]